This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agilon Health (AGL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of -127.27% and -4.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
BrightSpring Health Services, Inc. (BTSG) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
BrightSpring Health Services, Inc. (BTSG) delivered earnings and revenue surprises of +15.79% and +5.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strength Seen in Progyny (PGNY): Can Its 13.2% Jump Turn into More Strength?
by Zacks Equity Research
Progyny (PGNY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?
by Zacks Equity Research
Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
by Zacks Equity Research
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?
by Zacks Equity Research
Brainsway (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
RGC Resources (RGCO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last?
by Zacks Equity Research
GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength?
by Zacks Equity Research
Mobileye (MBLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 6.67% and 6.60%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
GDRX vs. PGNY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GDRX vs. PGNY: Which Stock Is the Better Value Option?
Solventum Q1 Earnings Likely to Reflect Higher Costs & Expenses
by Zacks Equity Research
SOLV's Q1 performance is likely to have been hurt by below-par revenue growth in several markets, coupled with currency headwinds. Improved pricing might have offset the sales decline.
Will Applied Sterilization Growth Help STE Beat Q4 Earnings Estimates?
by Zacks Equity Research
STERIS is expected to have experienced an increase in bioprocessing demand in the fourth quarter.
MCK Stock Up 24% YTD: Should You Buy, Hold or Sell Before Q4 Earnings?
by Zacks Equity Research
McKesson's fourth-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates?
by Zacks Equity Research
COR's fiscal second-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.
Progyny (PGNY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Progyny (PGNY) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Progyny (PGNY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Lower Commercial Premiums Hurt Humana's Q4 Earnings?
by Zacks Equity Research
HUM's Q4 results are likely to suffer a blow due to escalating operating costs, partly offset by membership growth in the Individual and Group Medicare Advantage business lines.
All You Need to Know About Progyny (PGNY) Rating Upgrade to Buy
by Zacks Equity Research
Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Will Progyny (PGNY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Progyny (PGNY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Progyny (PGNY) Tops Q3 Earnings Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 8.11% and 2.78%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?